Recent Advances of Parathyroid Hormone on Osseointegration of Implants

doi:10.3969/j.issn.1005-4979.2015.05.013

Abstract

Abstract: Parathyroid hormone(PTH) is widely used in the treatment of osteoporosis of skeletal system, because it plays an important role in calcium and phosphate metabolism. It was found that PTH has the dual effects of promoting bone formation and bone resorption in the process of bone tissue metabolism.The final effects was closely related to the factors, such as the way of administration and dosage. In addition, it has been demonstrated that PTH has a positive effect on osseointegration. But the mechanism needs further investigation. This article makes a collective review of PTH on osseointegration of implants.

Key words: parathyroid hormone, implant, osseointegration

摘要： 甲状旁腺激素（parathyroid hormone, PTH）因具有调节机体钙、磷代谢的重要作用，而被广泛应用于骨质疏松症的临床治疗。研究发现PTH在骨组织代谢过程中具有促进骨形成和骨吸收的双重效应，其最终的作用效果与给药方式和剂量等因素有密切的关系。另外， PTH被证明对促进种植体骨结合具有积极作用。但是其具体作用机制、使用方法和剂量等问题仍待进一步研究。本文就目前关于甲状旁腺激素对种植体骨结合影响的研究作一综述。

关键词: 甲状旁腺激素； , 种植体； , 骨结合

CLC Number:

R782.13

WANG Xing-xing, WANG Da-lin. Recent Advances of Parathyroid Hormone on Osseointegration of Implants[J]. 《Journal of Oral and Maxillofacial Surgery》, 2015, 25(5): 368-.

王星星（综述）汪大林（审校）. 甲状旁腺激素对种植体骨结合影响的研究现状[J]. 《口腔颌面外科杂志》, 2015, 25(5): 368-.

/ / Recommend / Download Citations

URL: https://journal06.magtech.org.cn/Jweb_joms/EN/10.3969/j.issn.1005-4979.2015.05.013

https://journal06.magtech.org.cn/Jweb_joms/EN/Y2015/V25/I5/368

References

[1] 刘明, 潘薇, 陈德才. 甲状旁腺激素治疗骨质疏松症的研究进展[J]. 中华骨质疏松和骨矿盐疾病杂志, 2012, 5(2):151-156.

[2] Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism [J]. Trends Endocrinol Metab, 2004, 15(2):60-65.

[3] Farra R, Sheppard NF Jr, Mccabe L, et al. First-in-human testing of a wirelessly controlled drug delivery microchip [J]. Sci Transl Med, 2012, 4(122):122ra121.

[4] Nardi A , Ventura L , Cozzi L , et al. The bone anabolic therapy [J]. Aging Clin Exp Res, 2013, 25 Suppl 1:S121-S124.

[5] Onyia JE, Helvering LM, Gelbert L, et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray [J]. J Cell Biochem, 2005, 95(2):403-418.

[6] Li X, Liu H, Qin L, et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis [J]. J Biol Chem, 2007, 282(45):33086-33097.

[7] Jilka RL, O'brien CA, Ali AA, et al. Intermittent pth stimulates periosteal bone formation by actions on post-mitotic preosteoblasts [J]. Bone, 2009, 44(2): 275-286.

[8] Augustine M, Horwitz MJ. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis [J]. Curr Osteoporos Rep, 2013, 11(4):400-406.

[9] Tam CS, Heersche JN, Murray TM, et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration [J]. Endocrinology, 1982, 110(2):506-512.

[10] Datta NS, Abou-Samra AB. Pth and pthrp signaling in osteoblasts [J]. Cell Signal, 2009, 21(8):1245-1254.

[11] Fujita T, Meguro T, Fukuyama R, et al. New signaling pathway for parathyroid hormone and cyclic amp action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic amp [J]. J Biol Chem, 2002, 277(25):22191-22200.

[12] Cupp ME, Nayak SK, Adem AS, et al. Parathyroid hormone (pth) and pth-related peptide domains contributing to activation of different pth receptor-mediated signaling pathways [J]. J Pharmacol Exp Ther, 2013, 345(3):404-418.

[13] Swarthout JT, D'alonzo RC, Selvamurugan N, et al. Parathyroid hormone-dependent signaling pathways regulating genes in bone cells [J]. Gene, 2002, 282(1-2):1-17.

[14] Shimizu E, Selvamurugan N, Westendorf JJ, et al. Parathyroid hormone regulates histone deacetylases in osteoblasts [J]. Ann N Y Acad Sci, 2007, 1116: 349-353.

[15] Kwok S, Qin L, Partridge NC, et al. Parathyroid hormone stimulation and pka signaling of latent transforming growth factor-beta binding protein-1 (ltbp-1) mrna expression in osteoblastic cells [J]. J Cell Biochem, 2005, 95(5):1002-1011.

[16] Ishizuya T. effects of parathyroid hormone on bone metabolism: differences between intermittent and continuous treatment [J]. Clin Calcium, 2012, 22(3): 357-363.

[17] Frolik CA, Black EC, Cain RL, et al. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure [J]. Bone, 2003, 33(3):372-379.

[18] Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent pth [J]. Bone, 2007, 40(6):1434-1446.

[19] Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis [J]. N Engl J Med, 2001, 344(19):1434-1441.

[20] Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate [J]. N Engl J Med, 2005, 353(6):566-575.

[21] Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use [J]. Endocr Rev, 2005, 26(5):688-703.

[22] Miao D, He B, Karaplis AC, et al. Parathyroid hormone is essential for normal fetal bone formation [J]. J Clin Invest, 2002, 109(9):1173-1182.

[23] Qin L , Li X , Ko JK , et al. Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase [J]. J Biol Chem, 2005, 280(4):3104-3111.

[24] Onyia JE, Bidwell J, Herring J, et al. In vivo, human parathyroid hormone fragment (hpth 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats [J]. Bone, 1995, 17(5):479-484.

[25] Sowa H, Kaji H, Iu MF, et al. Parathyroid hormone-smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts [J]. J Biol Chem, 2003, 278(52):52240-52252.

[26] Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism [J]. J Biol Chem, 2003, 278(50):50259-50272.

[27] Schnoke M, Midura SB, Midura RJ. Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair [J]. Bone, 2009, 45(3):590-602.

[28] Leaffer D, Sweeney M, Kellerman LA, et al. Modulation of osteogenic cell ultrastructure by rs-23581, an analog of human parathyroid hormone (pth)-related peptide-(1-34), and bovine pth-(1-34) [J]. Endocrinology, 1995, 136(8):3624-3631.

[29] Kaji H. [parathyroid and bone. Effects of parathyroid hormone on bone resorption and formation: differences between intermittent and continuous treatment] [J]. Clin Calcium, 2007, 17(12):1836-1842.

[30] 于世凤. 骨吸收与骨形成[J]. 现代康复, 2001, 5(2):10-13.

[31] Chambers TJ, Fuller K, Mcsheehy PM, et al. The effects of calcium regulating hormones on bone resorption by isolated human osteoclastoma cells [J]. J Pathol, 1985, 145(4): 297-305.

[32] Mcsheehy PM, Chambers TJ. Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone [J]. Endocrinology, 1986, 118(2):824-828.

[33] 钱莹, 朱萍, 王伟铭, 等. 人甲状旁腺激素调节骨保护素及其配体基因表达的pka、pkc信号传导通路研究 [J]. 中国微循环, 2007, 11(5):293-295.

[34] Tyrovola JB, Spyropoulos MN, Makou M, et al. Root resorption and the OPG/RANKL/RANK system: a mini review [J]. J Oral Sci, 2008, 50(4):367-376.

[35] Hofbauer LC, Kuhne CA, Viereck V. The opg/rankl/rank system in metabolic bone diseases[J]. J Musculoskelet Neuronal Interact, 2004, 4(3):268-275.

[36] Ma YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human pth (1--38) in vivo is associated with sustained stimulation of rankl and inhibition of osteoprotegerin and gene-associated bone formation [J]. Endocrinology, 2001, 142(9):4047-4054.

[37] Szymczak J, Bohdanowicz-Pawlak A. Osteoprotegerin, rankl, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate [J]. Horm Metab Res, 2013, 45(10):759-764.

[38] Hadji P, Zanchetta JR, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures [J]. Osteoporos Int, 2012, 23(8):2141-2150.

[39] Mcneilly T, Mcnally C, Finch M, et al. Recombinant pth: a study of the outcome of teriparatide therapy for 138 patients with osteoporosis [J]. Ulster Med J, 2013, 82(2):89-93.

[40] Fogelman I, Fordham JN, Fraser WD, et al. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy [J]. Calcif Tissue Int, 2008, 83(2):85-92.

[41] Finkelstein JS, Wyland JJ, Lee H, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis [J]. J Clin Endocrinol Metab, 2010, 95(4):1838-1845.

[42] Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial [J]. J Bone Miner Res, 2005, 20(11):1905-1911.

[43] 夏维波. 骨质疏松症的联合治疗与序贯治疗 [J]. 中华骨质疏松和骨矿盐疾病杂志, 2011, 4(2):73-81.

[44] Anastasilakis AD, Polyzos SA, Avramidis A, et al. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide [J]. Horm Metab Res, 2009, 41(7):559-562.

[45] Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: Final results of the randomized, controlled european study of forsteo (eurofors) [J]. J Bone Miner Res, 2009, 24(4):726-736.

[46] Gabet Y, Muller R, Levy J, et al. Parathyroid hormone 1-34 enhances titanium implant anchorage in low-density trabecular bone: a correlative micro-computed tomographic and biomechanical analysis [J]. Bone, 2006, 39(2):276-282.

[47] Shirota T, Tashiro M, Ohno K, et al. Effect of intermittent parathyroid hormone (1-34) treatment on the bone response after placement of titanium implants into the tibia of ovariectomized rats [J]. J Oral Maxillofac Surg, 2003, 61(4):471-480.

[48] Ohkawa Y, Tokunaga K, Endo N. Intermittent administration of human parathyroid hormone (1-34) increases new bone formation on the interface of hydroxyapatitecoated titanium rods implanted into ovariectomized rat femora [J]. J Orthop Sci, 2008, 13(6):533-542.

[49] Almagro MI, Roman-Blas JA, Bellido M, et al. Pth [1-34] enhances bone response around titanium implants in a rabbit model of osteoporosis [J]. Clin Oral Implants Res, 2013, 24(9):1027-1034.

[50] Li YF, Li XD, Bao CY, et al. Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface [J]. Osteoporos Int, 2013, 24(3):1063-1071.

[51] Daugaard H, Elmengaard B, Andreassen TT, et al. Systemic intermittent parathyroid hormone treatment improves osseointegration of press-fit inserted implants in cancellous bone [J]. Acta Orthop, 2012, 83(4):411-419.

[52] Kuchler U, Luvizuto ER, Tangl S, et al. Short-term teriparatide delivery and osseointegration: a clinical feasibility study [J]. J Dent Res, 2011, 90(8):1001-1006.

[53] Valderrama P, Jung RE, Thoma DS, et al. Evaluation of parathyroid hormone bound to a synthetic matrix for guided bone regeneration around dental implants: a histomorphometric study in dogs [J]. J Periodontol, 2010, 81(5):737-747.

[54] Yu X, Wang L, Jiang X, et al. Biomimetic cap coating incorporated with parathyroid hormone improves the osseointegration of titanium implant [J]. J Mater Sci Mater Med, 2012, 23(9):2177-2186.

Please choose a citation manager

Content to export